Investors

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities

01/09/20

~ Expects to Report KEVEYIS ® (dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million , a 29 Percent Increase over 2018 Revenue of $16.8 Million ~ ~ Provides Full-Year 2020 KEVEYIS ® (dichlorphenamide) Revenue Guidance...

Read More
Strongbridge Biopharma plc Announces Additional Steps to Improve Operational Efficiencies and Appoints New Lead Independent Director

11/18/19

~ The Company Remains Focused on Completing the LOGICS Study and Submitting a New Drug Application (NDA) for RECORLEV™ (levoketoconazole), While Ensuring Continued Growth and Profitability of KEVEYIS® (dichlorphenamide) and Serving the Unmet Needs of the Primary Periodic Paralysis Community ~...

Read More

Investors

Investors

Corporate Profile

Press Releases

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities

Strongbridge Biopharma plc Announces Additional Steps to Improve Operational Efficiencies and Appoints New Lead Independent Director

Upcoming Events